Literature DB >> 19830424

Familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3.

Leo Joseph1, Sandra N Hing, Nadege Presneau, Paul O'Donnell, Tim Diss, Bernadine D Idowu, Selvanayagam Joseph, Adrienne Margaret Flanagan, David Delaney.   

Abstract

OBJECTIVE: To report on the biochemistry and clinical and genetic findings of two siblings, the younger sister presenting with recurrent bone pain of the radius and ulna, and medullary sclerosis, and the older brother with soft tissue calcific deposits (tumoral calcinosis) but who later developed bone pain. Both were found to be hyperphosphaturic.
MATERIALS AND METHODS: The index family comprised four individuals (father, mother, brother, sister). The affected siblings were the offspring of a non-consanguineous Indian family of Tamil origin. Bidirectional sequencing was performed on the DNA from the index family and on 160 alleles from a population of 80 unrelated unaffected control individuals of Tamil extraction and 72 alleles from individuals of non-Tamil origin.
RESULTS: Two symptomatic siblings were found to harbour previously unreported compound heterozygous missense UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-transferase; GALNT3) mutations in exon 4 c.842A>G and exon 5 c.1097T>G. This sequence variation was not detected in the control DNA. This is the first report of siblings exhibiting stigmata of familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome with documented evidence of autosomal recessive missense GALNT3 mutations.
CONCLUSION: The findings from this family add further evidence to the literature that familial tumoral calcinosis and hyperostosis-hyperphosphataemia syndrome are manifestations of the same disease and highlight the importance of appropriate metabolic and genetic investigations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830424     DOI: 10.1007/s00256-009-0808-5

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  19 in total

1.  Genetics of familial tumoral calcinosis.

Authors:  Shoji Ichikawa; Erik A Imel; Michael J Econs
Journal:  Am J Kidney Dis       Date:  2009-03       Impact factor: 8.860

Review 2.  FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

Authors:  Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Bone       Date:  2007-01-04       Impact factor: 4.398

3.  Ribbing disease: radiographic and biochemical characterization, lack of response to pamidronate.

Authors:  Navid Ziran; Suvimol Hill; Mary E Wright; Joseph Kovacs; Pamela Gehron Robey; Shlomo Wientroub; Michael T Collins
Journal:  Skeletal Radiol       Date:  2002-08-15       Impact factor: 2.199

Review 4.  Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis.

Authors:  H Narchi
Journal:  Pediatrics       Date:  1997-05       Impact factor: 7.124

5.  Tumoural calcinosis.

Authors:  P E Palmer
Journal:  Br J Radiol       Date:  1966-07       Impact factor: 3.039

6.  A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis.

Authors:  Orit Topaz; Margarita Indelman; Ilana Chefetz; Dan Geiger; Aryeh Metzker; Yoram Altschuler; Mordechai Choder; Dani Bercovich; Jouni Uitto; Reuven Bergman; Gabriele Richard; Eli Sprecher
Journal:  Am J Hum Genet       Date:  2006-08-24       Impact factor: 11.025

7.  An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

Authors:  Anna Benet-Pagès; Peter Orlik; Tim M Strom; Bettina Lorenz-Depiereux
Journal:  Hum Mol Genet       Date:  2004-12-08       Impact factor: 6.150

8.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

9.  Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.

Authors:  Shoji Ichikawa; Vincent Guigonis; Erik A Imel; Mélanie Courouble; Sophie Heissat; John D Henley; Andrea H Sorenson; Barbara Petit; Anne Lienhardt; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

10.  Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25-dihydroxycholecalciferol concentrations.

Authors:  M J Prince; P C Schaeffer; R S Goldsmith; A B Chausmer
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

View more
  9 in total

1.  Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.

Authors:  Shoji Ichikawa; Anthony M Austin; Amie K Gray; Matthew R Allen; Michael J Econs
Journal:  Endocrinology       Date:  2011-10-18       Impact factor: 4.736

2.  A mildly painful wrist mass.

Authors:  Wai Kan Tsang; Kwok Fai Godfrey Tam
Journal:  Skeletal Radiol       Date:  2014-03       Impact factor: 2.199

3.  Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis.

Authors:  Alan Yancovitch; Dov Hershkovitz; Margareta Indelman; Peter Galloway; Margo Whiteford; Eli Sprecher; Esra Kılıç
Journal:  J Bone Miner Metab       Date:  2011-02-25       Impact factor: 2.626

Review 4.  Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.

Authors:  M Chakhtoura; M S Ramnitz; N Khoury; G Nemer; N Shabb; A Abchee; A Berberi; M Hourani; M Collins; S Ichikawa; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2018-06-20       Impact factor: 4.507

5.  Familial tumoral calcinosis in two Chinese patients: a case series.

Authors:  Che Zhang; Jiaowei Gu; Xiaoli Cheng; Kui Xiong
Journal:  J Med Case Rep       Date:  2011-08-19

6.  Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.

Authors:  Lihao Sun; Lin Zhao; Lianjun Du; Peipei Zhang; Minjia Zhang; Min Li; Tingting Liu; Lei Ye; Bei Tao; Hongyan Zhao; Jianmin Liu; Xiaoyi Ding
Journal:  Bone Res       Date:  2016-11-08       Impact factor: 13.567

7.  A novel FGF23 mutation in hyperphosphatemic familial tumoral calcinosis and its deleterious effect on protein O-glycosylation.

Authors:  Qingyao Zuo; Weili Yang; Baoyue Liu; Dong Yan; Zhixin Wang; Hong Wang; Wei Deng; Xi Cao; Jinkui Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

8.  A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.

Authors:  Christopher T Esapa; Rosie A Head; Jeshmi Jeyabalan; Holly Evans; Tertius A Hough; Michael T Cheeseman; Eugene G McNally; Andrew J Carr; Gethin P Thomas; Matthew A Brown; Peter I Croucher; Steve D M Brown; Roger D Cox; Rajesh V Thakker
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

Review 9.  Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.

Authors:  Silje Rafaelsen; Stefan Johansson; Helge Ræder; Robert Bjerknes
Journal:  BMC Genet       Date:  2014-09-24       Impact factor: 2.797

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.